Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 454.81M P/E - EPS this Y -118.30% Ern Qtrly Grth -
Income -57.47M Forward P/E 7.18 EPS next Y 278.30% 50D Avg Chg -1.00%
Sales 317.68M PEG 1.78 EPS past 5Y - 200D Avg Chg -26.00%
Dividend N/A Price/Book 6.77 EPS next 5Y -8.89% 52W High Chg -50.00%
Recommedations 2.70 Quick Ratio 3.92 Shares Outstanding 41.83M 52W Low Chg 24.00%
Insider Own 3.13% ROA -7.23% Shares Float 34.49M Beta 0.88
Inst Own 81.30% ROE -64.02% Shares Shorted/Prior 10.14M/9.43M Price 10.91
Gross Margin 99.80% Profit Margin -19.39% Avg. Volume 1,374,024 Target Price 19.00
Oper. Margin 1.85% Earnings Date Feb 29 Volume 1,559,312 Change 3.90%
About Intercept Pharmaceuticals, Inc.

Intercept Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat progressive non-viral liver diseases in the United States, Europe, and Canada. The company markets Ocaliva, a farnesoid X receptor agonist used for the treatment of primary biliary cholangitis in combination with ursodeoxycholic acid in adults. It is also developing Ocaliva for various indications, including nonalcoholic steatohepatitis and NASH; and other product candidates in various stages of clinical and preclinical development. The company has a license agreement with Aralez Pharmaceuticals Canada Inc. to develop and commercialize bezafibrate in the United States. It markets its products through an internal commercial organization and third-party distributors. The company was incorporated in 2002 and is headquartered in Morristown, New Jersey. As of November 8, 2023, Intercept Pharmaceuticals, Inc. operates as a subsidiary of Alfasigma S.p.A..

ICPT Chatroom

User Image DontBadgerMe Posted - 1 week ago

$NDRA $VKTX $MDGL $ICPT go to the Echosens website.and look at the global FibroScan locator and you'll see how far behind Endra is

User Image BearBullyJack Posted - 1 week ago

$NDRA can someone get me up to speed? Had an investment in this 4 years ago and sold after a small gain because wasn’t getting the price movement I was hoping for from positive results from $VKTX $MDGL, and at the time $ICPT. What reason has this not taken off? Approval in EU, alternative to biopsies? Faster diagnosis? I just can’t wrap my mind around it but maybe someone can get me up to speed as I have not followed it for years now. Looking to jump back in, thanks

User Image TraderLawJCF Posted - 1 week ago

$MDGL Where’s the fraud CEO of $ICPT from 2014 thinking he had miracle rejecting b/o offers…selling shared every year…on his yacht

User Image BearBullyJack Posted - 1 week ago

$MDGL $VKTX I’ve seen these guys grow nearly from their infancy. My conviction has remained strong through and through and given the data provided over the last few years and in comparison to others in this space, particularly $ICPT FDA review, Madrigal will surely be approved and sell well. Viking will have a good chance to share that market share and be a menace when it too reaches the market for sales but Madrigal has a solid 2 years to make a mark in their market share and get real sale numbers up. Hold strong folks, this one has room to grow $400+ and Viking at $150+ especially given their GLP-1 and the not so known but absolutely freakishly good drug VK5211

User Image rencofilstat Posted - 2 weeks ago

$ICPT Go fail another FDA trial due to safety.

User Image rencofilstat Posted - 2 weeks ago

$ICPT sucks ass farts.

User Image All_just_a_game Posted - 3 weeks ago

$MDGL This is from 2016 when I acquired my MDGL stake via Synta. Thank god Becky was shagging Paul and they merged companies otherwise I would have been a permanent bankrupt bag holder. 8 years later.. ICPT GILD Genfit. Failed. Madrigal..2 weeks from being only approved therapy. ☘️ ☘️☘️☘️☘️☘️GL After PhIII failure Synta announces merger, shifts R&D focus By Ben Adams Apr 14, 2016 9:53am Synta joins a long and growing list of biotechs and pharma moving in on the NASH space, which analysts believe could be worth $40 billion in the next decade. Intercept ($ICPT), Gilead ($GILD) and French biotech Genfit are just some of the players in this emerging field which aim to develop the first ever treatments for the liver scarring disease--a disease caused predominately by the rising rates of obesity and diabetes.

User Image Stock_Titan Posted - 02/29/24

$ICPT Intercept Announces FDA Acceptance of Supplemental New Drug Application for Ocaliva® (obeticholic acid) for the Treatment of PBC https://www.stocktitan.net/news/ICPT/intercept-announces-fda-acceptance-of-supplemental-new-drug-r05mdkc22mni.html

User Image GSMITH10107 Posted - 1 month ago

$IVA is it possible $IVA could potentially be the leader in NASH ? i know $ICPT got bought out and $MDGL is launching this year, but thsi graphic has to mean alot..

User Image GSMITH10107 Posted - 1 month ago

$IVA 194 million dollar market cap.. well into phase 3 compared to NASH players $ICPT bought out for 795 million $MDGL 4.1 billion $AKRO 1.1 billion pretty shocking graphic if you ask me when do i get my correction?

User Image MMCT Posted - 1 month ago

$MDGL @@All_just_a_game @CC_Abbott Could u both point out on a comment why $ICPT got rejected by Adcom and why We have a better chance 😄

User Image bbear Posted - 1 month ago

$ICPT never forget some assclown at BOA slapped a $800 PT on this in 2014. she then left BOA to work for the company.

User Image tickeron Posted - 2 months ago

$ICPT $ATXS $CBAY $CBAY, $ARDX, $VKTX Lead Biotech Sector Surge with Remarkable +10.76% Weekly Performance Gain. Robots for this group tickers : Swing Trader, Long Only: Growth Model (FA) - 30-day Annualized Return +77% Swing Trader for.... https://srnk.us/go/4967249

User Image ChartMill Posted - 2 months ago

Besides having an excellent technical rating, $ICPT also presents a decent setup pattern. https://www.chartmill.com/stock/quote/ICPT/technical-analysis?key=bdeece9e-091e-4ba6-8f28-cd4984a41b41&utm_source=SETUP&utm_medium=stocktwits&utm_campaign=TA&utm_content=ICPT

User Image tickeron Posted - 2 months ago

$ICPT $ATXS $CBAY $ATXS, $CBAY, $ARDX, $VKTX: Metabolic Biotech Stocks Surge 10.24% in a Week. Robots for this group tickers : Swing Trader, Long Only: Growth Model (FA) - 30-day Annualized Return +71% Trend Trader,.... https://srnk.us/go/4965250

User Image US_Bull Posted - 3 months ago

$ICPT People were saying the exact same thing on the ICPT (Mciced can confirm) daily no sound crickets and boom make no mistake same thing will happen here. BP would have to be outright stupid not to want LUP in their portfolio a potential 7-800 million drug in the right hands it is basically given easy money and our patent portfolio is iron clad strong (no one would dare challenge it again). Just patience. SP is slowly getting to a level where BO can reach a fair level 22-26$ should do the trick.

User Image YasmyGuy Posted - 3 months ago

@Gymnut $XCN.X $ICPT Cho Cho! Not selling either!!!

User Image MarketBeat Posted - 3 months ago

Intercept Pharmaceuticals initiated by StockNews.com at hold. www.marketbeat.com/stocks/NASDAQ/ICPT/price-target/ $ICPT

User Image thePistolPete Posted - 3 months ago

$ICPT the glory days

User Image 75guyjax Posted - 3 months ago

$ICPT sugar pill??? Why slander, sir??

User Image cctranscripts Posted - 4 months ago

Securities registration termination [Section 12(g)] https://www.conferencecalltranscripts.org/summary/?id=12723554 $ICPT

User Image stockilluminati Posted - 4 months ago

$ICPT https://www.stockilluminati.com/icpt/filings.php - Intercept Pharmaceuticals, Inc. - Common Stock files form 15-12G today, check out the details.

User Image stockilluminati Posted - 4 months ago

$ICPT https://www.stockilluminati.com/icpt/news.php - Circling Back On CymaBay Therapeutics

User Image cctranscripts Posted - 4 months ago

Notice of Effectiveness https://www.conferencecalltranscripts.org/summary/?id=12709981 $ICPT

User Image cctranscripts Posted - 4 months ago

Notice of Effectiveness https://www.conferencecalltranscripts.org/summary/?id=12709811 $ICPT

User Image cctranscripts Posted - 4 months ago

Notice of Effectiveness https://www.conferencecalltranscripts.org/summary/?id=12709797 $ICPT

User Image tickeron Posted - 4 months ago

Intercept Pharmaceuticals to report earnings on November 13, 2023. Earnings per share (EPS) estimate: $-0.23 $ICPT https://srnk.us/go/4913828

User Image Stock_Titan Posted - 4 months ago

$ICPT Intercept Announces New Phase 2 Data Showing Significant Impact of OCA-Bezafibrate Combination on Normalization of Multiple Key Biomarkers of PBC-Induced Liver Damage at AASLD The Liver Meeting® 2023 https://www.stocktitan.net/news/ICPT/intercept-announces-new-phase-2-data-showing-significant-impact-of-33xujuhzywti.html

User Image neelsen01 Posted - 4 months ago

$CHRS With this disappointing quarter revenue release, and foreseeing ASP pressure on biosimilars over the next couple years, this company may very well end up like $ICPT…

User Image tickeron Posted - 4 months ago

$ICPT enters bearish trend https://srnk.us/go/4911537

Analyst Ratings
B. Riley Securities Neutral Sep 27, 23
RBC Capital Sector Perform Sep 27, 23
HC Wainwright & Co. Neutral Sep 27, 23
Canaccord Genuity Hold Sep 27, 23
HC Wainwright & Co. Buy Aug 3, 23
Canaccord Genuity Buy Aug 3, 23
HC Wainwright & Co. Buy Jul 13, 23
Canaccord Genuity Buy Jun 29, 23
RBC Capital Sector Perform Jun 26, 23